Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

| April 6, 2015 | 0 Comments

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML).

Originally posted here:
Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Tags: , , , , , , , , , ,

Category: Recent News

About the Author ()

Leave a Reply